October is Liver Cancer Awareness Month, an annual national awareness campaign centered around raising the voices of those impacted by liver cancer, showing the importance of liver cancer screening and prevention, and examining the future of the liver cancer landscape worldwide.
Each year tens of thousands of people hear the words “You have liver cancer” and sadly these numbers are increasing, unlike many other cancers.
The statistics are frightening and staggering, and the trends may paint a picture that seems insurmountable, but they also provide an opportunity. According to the American Cancer Society 70% of liver cancer cases could be prevented. We also know that obesity, nonalcoholic steatohepatitis (NASH), the opioid epidemic, and HBV are all critical drivers in the rise of liver cancer. A disease that is interconnected in so many ways, and known to be preventable, provides an opportunity to collaborate with our colleagues, peers, and experts in other disease states.
To answer the call of all impacted by liver cancer, we must collaborate and commit to improving liver cancer outcomes. One voice is never as effective as many united behind a single cause.
October is Liver Cancer Awareness Month, an annual national awareness campaign centered around raising the voices of those impacted by liver cancer, showing the importance of liver cancer screening and prevention, and examining the future of the liver cancer landscape worldwide.
To read more, click here.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Building Accountability Into GLP-1 Benefit Design: Lessons From Delaware and Philadelphia
August 20th 2025Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and data-driven strategies in Philadelphia, Pennsylvania, and Wilmington, Delaware, for sustainable health programs.
Read More